Legend Biotech (NASDAQ:LEGN – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $179.00 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Legend Biotech Stock Up 3.2 %
Shares of LEGN opened at $35.26 on Monday. The company’s 50-day simple moving average is $35.36 and its 200-day simple moving average is $41.45. The stock has a market capitalization of $6.44 billion, a PE ratio of -37.12 and a beta of 0.19. Legend Biotech has a 1 year low of $30.17 and a 1 year high of $69.24. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98.
Analyst Ratings Changes
LEGN has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price on shares of Legend Biotech in a report on Tuesday, January 21st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $78.00 target price on shares of Legend Biotech in a report on Monday, December 30th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $79.50.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Featured Stories
- Five stocks we like better than Legend Biotech
- With Risk Tolerance, One Size Does Not Fit All
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- What Investors Need to Know About Upcoming IPOs
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
